Weight training tames one inflammatory marker in age-related muscle loss

Sarcopenia, the age-related loss of muscle mass and strength, is especially common among Asian populations, and international guidelines from the ICFSR task force already recommend resistance training as a primary treatment. Inflammatory biomarkers are used as indicators of sarcopenia, which raises a practical question: does the training that rebuilds muscle also calm the inflammation that tracks the condition? Until now there has been no conclusive evidence on whether resistance training shifts these markers in Asian adults with sarcopenia, which is the gap this review set out to close.

The researchers systematically searched four databases up to October 2023 for randomised controlled trials testing resistance training in Asian participants with sarcopenia. They focused on four inflammatory biomarkers: interleukin-6, tumour necrosis factor alpha, C-reactive protein and interleukin-10. The review was registered in advance in the PROSPERO database. Six eligible trials were found, covering 278 participants in total, and their results were pooled to estimate the overall effect of training on each marker.

Resistance training produced a significant fall in IL-6, with a pooled weighted mean difference of 0.73 units across five trials. The other three markers told a different story: TNF-α, CRP and IL-10 all showed no significant change after training. Subgroup analyses suggested that factors such as the participants' sex, the type of intervention, and the frequency, period and duration of training could influence some of the biomarker results, though these findings were exploratory rather than definitive.

The finding supports the guideline position that resistance training is a sensible primary treatment for sarcopenia, and adds a mechanistic layer by showing at least one inflammatory pathway responds. At the same time it complicates the popular idea that exercise broadly reverses inflammation, since three of the four markers stayed put. The authors call for further work to confirm the results and to explore how diet, body composition and medications might shape the inflammatory response to training.

If you or a family member trains to hold onto muscle with age, this is a reason to think some of the benefit may run through reduced inflammation, at least for one key marker. It is not a reason to expect resistance training to normalise every blood test, and the evidence base here is small and specific to Asian adults with diagnosed sarcopenia. The most robust message remains the one the guidelines already carry: resistance training is the recommended first-line approach for sarcopenia, and this review adds one piece to the picture of why it may help.